- Home
- INCY
INCY
Incyte Corp.
as 06-20-2025 4:00pm EST
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 13.4B | IPO Year: | 1993 |
| Target Price: | $73.81 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Hold | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.10 | EPS Growth: | -97.06 |
| 52 Week Low/High: | $53.56 - $83.95 | Next Earning Date: | 07-29-2025 |
| Revenue: | $4,413,226,000 | Revenue Growth: | 17.13% |
| Revenue Growth (this year): | 13.29% | Revenue Growth (next year): | 10.47% |
Stock Insider Trading Activity of Incyte Corp. (INCY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Denton Sheila A. | INCY | EVP & General Counsel | Jun 3 '25 | Sell | $68.00 | 1,795 | $122,060.00 | 26,504 | |
| Tray Thomas | INCY | Principal Accounting Officer | May 30 '25 | Sell | $65.29 | 1,614 | $105,515.61 | 22,654 |
Latest Incyte Corp. News
INCY Breaking Stock News: Dive into INCY Ticker-Specific Updates for Smart Investing
MT Newswires
18 hours ago
Incyte Says FDA Extends Review Period for Ruxolitinib Cream
Business Wire
18 hours ago
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
Insider Monkey
19 hours ago
Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions
Zacks
2 days ago
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
MT Newswires
3 days ago
Incyte's Drug to Treat Follicular Lymphoma Receives FDA Approval
Business Wire
3 days ago
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
Simply Wall St.
4 days ago
Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value
Zacks
4 days ago
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
Compare INCY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INCY Incyte Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.